CA2697262A1 - Compositions of humanized notch fusion proteins and methods of treatment - Google Patents
Compositions of humanized notch fusion proteins and methods of treatment Download PDFInfo
- Publication number
- CA2697262A1 CA2697262A1 CA 2697262 CA2697262A CA2697262A1 CA 2697262 A1 CA2697262 A1 CA 2697262A1 CA 2697262 CA2697262 CA 2697262 CA 2697262 A CA2697262 A CA 2697262A CA 2697262 A1 CA2697262 A1 CA 2697262A1
- Authority
- CA
- Canada
- Prior art keywords
- fusion protein
- sequence
- subject
- seq
- notch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 276
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 276
- 238000000034 method Methods 0.000 title claims abstract description 94
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title description 103
- 108010070047 Notch Receptors Proteins 0.000 claims abstract description 386
- 102000005650 Notch Receptors Human genes 0.000 claims abstract description 381
- 241000282414 Homo sapiens Species 0.000 claims abstract description 337
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 186
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 136
- 230000033115 angiogenesis Effects 0.000 claims abstract description 67
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 42
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 33
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 31
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 150000001413 amino acids Chemical class 0.000 claims description 350
- 102000001753 Notch4 Receptor Human genes 0.000 claims description 139
- 108010029741 Notch4 Receptor Proteins 0.000 claims description 139
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 claims description 123
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 94
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 91
- 239000002773 nucleotide Substances 0.000 claims description 62
- 125000003729 nucleotide group Chemical group 0.000 claims description 62
- 239000003112 inhibitor Substances 0.000 claims description 46
- 201000011510 cancer Diseases 0.000 claims description 36
- 230000002792 vascular Effects 0.000 claims description 32
- 230000012010 growth Effects 0.000 claims description 27
- 102000001760 Notch3 Receptor Human genes 0.000 claims description 20
- 108010029756 Notch3 Receptor Proteins 0.000 claims description 18
- 230000004614 tumor growth Effects 0.000 claims description 18
- 102000001756 Notch2 Receptor Human genes 0.000 claims description 15
- 108010029751 Notch2 Receptor Proteins 0.000 claims description 15
- 206010027476 Metastases Diseases 0.000 claims description 13
- 230000035168 lymphangiogenesis Effects 0.000 claims description 13
- 230000009401 metastasis Effects 0.000 claims description 13
- 230000001575 pathological effect Effects 0.000 claims description 12
- 208000011581 secondary neoplasm Diseases 0.000 claims description 11
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 10
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 9
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 8
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims description 8
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 8
- 210000004204 blood vessel Anatomy 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 208000028867 ischemia Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 229940124090 Platelet-derived growth factor (PDGF) receptor antagonist Drugs 0.000 claims description 5
- 108091008605 VEGF receptors Proteins 0.000 claims description 5
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- -1 PGIF Proteins 0.000 claims description 4
- 208000023516 stroke disease Diseases 0.000 claims description 4
- 101150029707 ERBB2 gene Proteins 0.000 claims description 3
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 3
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 3
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 3
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims description 3
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 3
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims description 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000004324 lymphatic system Anatomy 0.000 claims description 2
- 102000001759 Notch1 Receptor Human genes 0.000 claims 9
- 108010029755 Notch1 Receptor Proteins 0.000 claims 9
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 4
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 281
- 210000004027 cell Anatomy 0.000 description 181
- 108090000623 proteins and genes Proteins 0.000 description 164
- 102000004169 proteins and genes Human genes 0.000 description 143
- 235000018102 proteins Nutrition 0.000 description 142
- 230000014509 gene expression Effects 0.000 description 141
- 230000011664 signaling Effects 0.000 description 125
- 101000577163 Homo sapiens Neurogenic locus notch homolog protein 4 Proteins 0.000 description 117
- 102000047120 human NOTCH4 Human genes 0.000 description 116
- 230000000694 effects Effects 0.000 description 94
- 238000009472 formulation Methods 0.000 description 91
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 90
- 239000003446 ligand Substances 0.000 description 65
- 108020004459 Small interfering RNA Proteins 0.000 description 55
- 239000004055 small Interfering RNA Substances 0.000 description 55
- 230000004913 activation Effects 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 46
- 230000034303 cell budding Effects 0.000 description 45
- 150000007523 nucleic acids Chemical group 0.000 description 45
- 210000002889 endothelial cell Anatomy 0.000 description 38
- 230000005764 inhibitory process Effects 0.000 description 37
- 108091028043 Nucleic acid sequence Proteins 0.000 description 35
- 230000027455 binding Effects 0.000 description 34
- 230000004069 differentiation Effects 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 33
- 230000004927 fusion Effects 0.000 description 32
- 230000006870 function Effects 0.000 description 30
- 230000006698 induction Effects 0.000 description 27
- 102000005962 receptors Human genes 0.000 description 27
- 108020003175 receptors Proteins 0.000 description 27
- 230000001105 regulatory effect Effects 0.000 description 26
- 101150092640 HES1 gene Proteins 0.000 description 25
- 230000001419 dependent effect Effects 0.000 description 25
- 241000701161 unidentified adenovirus Species 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 24
- 230000005747 tumor angiogenesis Effects 0.000 description 24
- 238000003556 assay Methods 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 101150046266 foxo gene Proteins 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 238000001890 transfection Methods 0.000 description 21
- 239000000512 collagen gel Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 210000005166 vasculature Anatomy 0.000 description 20
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 19
- 238000003776 cleavage reaction Methods 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 230000007017 scission Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 238000011161 development Methods 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 18
- 239000000835 fiber Substances 0.000 description 18
- 230000037361 pathway Effects 0.000 description 18
- 101100506445 Mus musculus Helt gene Proteins 0.000 description 16
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 16
- 238000010361 transduction Methods 0.000 description 16
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 102100035194 Placenta growth factor Human genes 0.000 description 15
- 238000003501 co-culture Methods 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 14
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 230000003993 interaction Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 13
- 101710189714 Major cell-binding factor Proteins 0.000 description 13
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 13
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 102000009123 Fibrin Human genes 0.000 description 12
- 108010073385 Fibrin Proteins 0.000 description 12
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 12
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 230000003511 endothelial effect Effects 0.000 description 12
- 229950003499 fibrin Drugs 0.000 description 12
- 230000006459 vascular development Effects 0.000 description 12
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 11
- 102100031633 Chorionic somatomammotropin hormone-like 1 Human genes 0.000 description 11
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 11
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 10
- 101150044441 PECAM1 gene Proteins 0.000 description 10
- 238000010240 RT-PCR analysis Methods 0.000 description 10
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 10
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 210000003098 myoblast Anatomy 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 9
- 101710178181 Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 9
- 230000002491 angiogenic effect Effects 0.000 description 9
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000003038 endothelium Anatomy 0.000 description 9
- 239000012133 immunoprecipitate Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 7
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 7
- 108060008487 Myosin Proteins 0.000 description 7
- 102000003505 Myosin Human genes 0.000 description 7
- 206010029113 Neovascularisation Diseases 0.000 description 7
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 7
- 230000024245 cell differentiation Effects 0.000 description 7
- 238000000749 co-immunoprecipitation Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000003119 immunoblot Methods 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 230000001114 myogenic effect Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 210000002027 skeletal muscle Anatomy 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 108091006020 Fc-tagged proteins Proteins 0.000 description 6
- 102000013382 Gelatinases Human genes 0.000 description 6
- 108010026132 Gelatinases Proteins 0.000 description 6
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 6
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 6
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 102100038380 Myogenic factor 5 Human genes 0.000 description 6
- 101710099061 Myogenic factor 5 Proteins 0.000 description 6
- 102100032970 Myogenin Human genes 0.000 description 6
- 108010056785 Myogenin Proteins 0.000 description 6
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000011198 co-culture assay Methods 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 102000058223 human VEGFA Human genes 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 5
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 5
- 101150029234 Hes5 gene Proteins 0.000 description 5
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 230000005913 Notch signaling pathway Effects 0.000 description 5
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 5
- 238000002679 ablation Methods 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000001365 lymphatic vessel Anatomy 0.000 description 5
- 238000000059 patterning Methods 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 206010001258 Adenoviral infections Diseases 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 4
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 4
- 108091008794 FGF receptors Proteins 0.000 description 4
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 4
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010050254 Presenilins Proteins 0.000 description 4
- 102000015499 Presenilins Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 208000032594 Vascular Remodeling Diseases 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000033026 cell fate determination Effects 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012761 co-transfection Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 210000001087 myotubule Anatomy 0.000 description 4
- 230000008910 negative regulation of myoblast differentiation Effects 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 238000003571 reporter gene assay Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 108091006107 transcriptional repressors Proteins 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 230000007556 vascular defect Effects 0.000 description 4
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 108010049777 Ankyrins Proteins 0.000 description 3
- 102000008102 Ankyrins Human genes 0.000 description 3
- 101100510615 Caenorhabditis elegans lag-2 gene Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 108700007800 Drosophila N Proteins 0.000 description 3
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 3
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 3
- 101000577199 Homo sapiens Neurogenic locus notch homolog protein 2 Proteins 0.000 description 3
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 description 3
- 101100348097 Mus musculus Ncor2 gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710170213 Protein jagged-2 Proteins 0.000 description 3
- 102100032733 Protein jagged-2 Human genes 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000006481 angiogenic pathway Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 238000007804 gelatin zymography Methods 0.000 description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000009131 signaling function Effects 0.000 description 3
- 230000022379 skeletal muscle tissue development Effects 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 210000005167 vascular cell Anatomy 0.000 description 3
- 230000004862 vasculogenesis Effects 0.000 description 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- SQJQIAXXTBPHBR-SCGRZTRASA-N 2-aminoacetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H](N)CCCNC(N)=N SQJQIAXXTBPHBR-SCGRZTRASA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 2
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 2
- 101100074828 Caenorhabditis elegans lin-12 gene Proteins 0.000 description 2
- 101000584736 Ciona intestinalis Suppressor of hairless homolog Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 description 2
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 2
- 101150106966 FOXO1 gene Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 208000033157 Hepatic cystic hamartoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108700003486 Jagged-1 Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 101100348845 Mus musculus Notch3 gene Proteins 0.000 description 2
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 102100032702 Protein jagged-1 Human genes 0.000 description 2
- 108700037966 Protein jagged-1 Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101100348843 Rattus norvegicus Notch2 gene Proteins 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000004712 air sac Anatomy 0.000 description 2
- 210000000648 angioblast Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000006041 cell recruitment Effects 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003566 hemangioblast Anatomy 0.000 description 2
- 102000045609 human NOTCH1 Human genes 0.000 description 2
- 102000046883 human NOTCH2 Human genes 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000016457 liver mesenchymal hamartoma Diseases 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 2
- 210000001077 lymphatic endothelium Anatomy 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 238000007491 morphometric analysis Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000021268 myoblast fusion Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000007030 peptide scission Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000010379 pull-down assay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000007727 signaling mechanism Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 210000001189 slow twitch fiber Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 101100421133 Caenorhabditis elegans sel-10 gene Proteins 0.000 description 1
- 101100465890 Caenorhabditis elegans sel-12 gene Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- 108700019125 Drosophila Em7-HLH Proteins 0.000 description 1
- 108700020432 Drosophila hairy Proteins 0.000 description 1
- 108700020784 Drosophila su Proteins 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001023028 Gallus gallus Myogenin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
- 101100456626 Homo sapiens MEF2A gene Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 101150088608 Kdr gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 102000041373 MRF family Human genes 0.000 description 1
- 108091075959 MRF family Proteins 0.000 description 1
- 101150094019 MYOG gene Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 description 1
- 101100079042 Mus musculus Myef2 gene Proteins 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 108010081823 Myocardin Proteins 0.000 description 1
- 102100030217 Myocardin Human genes 0.000 description 1
- 102100021148 Myocyte-specific enhancer factor 2A Human genes 0.000 description 1
- 102100038379 Myogenic factor 6 Human genes 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 1
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 1
- 102400000545 Notch 2 intracellular domain Human genes 0.000 description 1
- 101800001731 Notch 2 intracellular domain Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102100037265 Podoplanin Human genes 0.000 description 1
- 101710118150 Podoplanin Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 1
- 229940121773 Secretase inhibitor Drugs 0.000 description 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 description 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 102000013534 Troponin C Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000000453 cell autonomous effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 235000015246 common arrowhead Nutrition 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 101150051928 d14 gene Proteins 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MXCPYJZDGPQDRA-UHFFFAOYSA-N dialuminum;2-acetyloxybenzoic acid;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3].CC(=O)OC1=CC=CC=C1C(O)=O MXCPYJZDGPQDRA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000437 effect on angiogenesis Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 229910000078 germane Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000008567 mammal embryogenesis Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 101150014102 mef-2 gene Proteins 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000004070 myogenic differentiation Effects 0.000 description 1
- 108010084677 myogenic factor 6 Proteins 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008905 regulation of myoblast differentiation Effects 0.000 description 1
- 238000001403 relative X-ray reflectometry Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 101150117735 sel-10 gene Proteins 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003875 slow muscle fiber Anatomy 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96605207P | 2007-08-23 | 2007-08-23 | |
| US60/966,052 | 2007-08-23 | ||
| PCT/US2008/010045 WO2009025867A2 (en) | 2007-08-23 | 2008-08-22 | Compositions of humanized notch fusion proteins and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2697262A1 true CA2697262A1 (en) | 2009-02-26 |
Family
ID=40378882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2697262 Abandoned CA2697262A1 (en) | 2007-08-23 | 2008-08-22 | Compositions of humanized notch fusion proteins and methods of treatment |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9127085B2 (enExample) |
| EP (1) | EP2193143B1 (enExample) |
| JP (2) | JP2010536855A (enExample) |
| KR (1) | KR20100076947A (enExample) |
| CN (1) | CN101883786A (enExample) |
| AU (1) | AU2008289462B2 (enExample) |
| BR (1) | BRPI0815291A2 (enExample) |
| CA (1) | CA2697262A1 (enExample) |
| IL (2) | IL204111A (enExample) |
| MX (1) | MX2010002053A (enExample) |
| NZ (3) | NZ618129A (enExample) |
| RU (1) | RU2532830C2 (enExample) |
| SG (1) | SG183763A1 (enExample) |
| WO (1) | WO2009025867A2 (enExample) |
| ZA (1) | ZA201001427B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| WO2005111072A2 (en) * | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
| WO2007103114A2 (en) | 2006-03-07 | 2007-09-13 | The Brigham & Women's Hospital, Inc. | Notch inhibition in the treatment or prevention of atherosclerosis |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| EP2032166B1 (en) | 2006-06-13 | 2013-04-10 | OncoMed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| CA2676008A1 (en) | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| EP2262890A1 (en) * | 2008-02-22 | 2010-12-22 | Vrije Universiteit Brussel | Method for generating islet beta cells from dedifferentiated exocrine pancreatic cells |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| PT2307051E (pt) | 2008-07-08 | 2015-05-21 | Oncomed Pharm Inc | Antagonistas e agentes de ligação a notch e métodos de utilização dos mesmos |
| US9475855B2 (en) | 2008-08-22 | 2016-10-25 | The Trustees Of Columbia University In The City Of New York | Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling |
| EP2493497A4 (en) * | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| AU2011205316B2 (en) | 2010-01-13 | 2015-05-28 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| TW201329105A (zh) | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類ｎｏｔｃｈ１引誘物 |
| CN104870476B (zh) * | 2012-11-21 | 2018-04-13 | 药物抗体公司 | 靶向vegfr‑2和dll4的双靶向抗体及包含它的药物组合物 |
| WO2014141064A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
| US20160030513A1 (en) * | 2013-03-15 | 2016-02-04 | The Trustees Of Columbia University In The City Of New York | Notch1 Decoy Antagonists Protect From Obesity-Induced Insulin Resistance and Fatty Liver |
| WO2014151950A1 (en) * | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Notch1 decoy antagonists protect from obesity-induced insulin resistance and fatty liver |
| JP6726174B2 (ja) * | 2015-04-16 | 2020-07-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ヒトＮｏｔｃｈ４抗体 |
| US11026996B2 (en) | 2016-05-25 | 2021-06-08 | The Trustees Of Columbia University In The City Of New York | Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling |
| US11325957B2 (en) | 2017-06-19 | 2022-05-10 | Cell Design Labs, Inc. | Methods and compositions for reducing the immunogenicity of chimeric notch receptors |
| CA3082782A1 (en) | 2017-11-16 | 2019-05-23 | The Regents Of The University Of California | Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof |
| CN108707628B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | 斑马鱼notch2基因突变体的制备方法 |
| CN108753833B (zh) * | 2018-05-28 | 2021-12-03 | 上海海洋大学 | 斑马鱼notch3基因突变体的制备方法 |
| CN109467598B (zh) * | 2018-11-28 | 2021-11-09 | 生命谷（海南）生物科技股份有限公司 | 肿瘤相关基因notch1突变短肽及其应用 |
| US20230174633A1 (en) * | 2020-03-30 | 2023-06-08 | Memorial Sloan Kettering Cancer Center | Methods and compositions for modulating lipid storage in adipose tissue |
| CN112961250B (zh) * | 2021-03-01 | 2023-06-06 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
| CN114062682A (zh) * | 2021-11-10 | 2022-02-18 | 厦门大学附属心血管病医院 | Notch3作为检测靶标的应用 |
| CN116790603B (zh) * | 2023-08-18 | 2023-10-31 | 成都中科奥格生物科技有限公司 | 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE20030749A1 (en) | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
| US6716974B1 (en) | 1996-05-31 | 2004-04-06 | Maine Medical Center Research Institute | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| FR2751986B1 (fr) | 1996-08-01 | 1998-12-31 | Inst Nat Sante Rech Med | Gene implique dans le cadasil, methode de diagnostic et application therapeutique |
| GB9623236D0 (en) * | 1996-11-07 | 1997-01-08 | Imperial College | Notch |
| US6379925B1 (en) | 1997-06-18 | 2002-04-30 | The Trustees Of Columbia University In The City Of New York | Angiogenic modulation by notch signal transduction |
| US6703221B1 (en) | 1999-08-19 | 2004-03-09 | Chiron Corporation | Notch receptor ligands and uses thereof |
| GB9927328D0 (en) | 1999-11-18 | 2000-01-12 | Lorantis Ltd | Immunotherapy |
| US6689744B2 (en) * | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| EP1448599A2 (en) | 2001-11-14 | 2004-08-25 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
| WO2003087159A2 (en) | 2002-04-05 | 2003-10-23 | Lorantis Limited | Modulators of the notch signalling pathway and uses thereof in medical treatment |
| JP2006513260A (ja) | 2002-08-03 | 2006-04-20 | ロランティス リミテッド | Ｎｏｔｃｈシグナル伝達経路調節因子の複合体およびその薬物治療への使用 |
| JP2006515177A (ja) * | 2002-09-10 | 2006-05-25 | ロランティス リミテッド | Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置 |
| WO2005111072A2 (en) * | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
| US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| WO2006047878A1 (en) | 2004-11-03 | 2006-05-11 | British Columbia Cancer Agency Branch | Cancer therapeutics and methods for their use |
| CN101277672A (zh) * | 2005-07-29 | 2008-10-01 | 通用医疗公司 | 用于减少皮肤损伤的方法和组合物 |
| PE20081264A1 (es) * | 2006-10-19 | 2008-10-01 | Genentech Inc | Anticuerpos agonistas anti-notch3 |
| US9475855B2 (en) | 2008-08-22 | 2016-10-25 | The Trustees Of Columbia University In The City Of New York | Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling |
| TW201329105A (zh) | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類ｎｏｔｃｈ１引誘物 |
-
2008
- 2008-08-22 NZ NZ618129A patent/NZ618129A/en not_active IP Right Cessation
- 2008-08-22 RU RU2010110812/10A patent/RU2532830C2/ru not_active IP Right Cessation
- 2008-08-22 BR BRPI0815291 patent/BRPI0815291A2/pt not_active IP Right Cessation
- 2008-08-22 NZ NZ60017108A patent/NZ600171A/en not_active IP Right Cessation
- 2008-08-22 NZ NZ583649A patent/NZ583649A/en not_active IP Right Cessation
- 2008-08-22 SG SG2012062477A patent/SG183763A1/en unknown
- 2008-08-22 CN CN2008801120573A patent/CN101883786A/zh active Pending
- 2008-08-22 WO PCT/US2008/010045 patent/WO2009025867A2/en not_active Ceased
- 2008-08-22 AU AU2008289462A patent/AU2008289462B2/en not_active Ceased
- 2008-08-22 KR KR20107006041A patent/KR20100076947A/ko not_active Ceased
- 2008-08-22 EP EP08795559.7A patent/EP2193143B1/en active Active
- 2008-08-22 US US12/733,329 patent/US9127085B2/en not_active Expired - Fee Related
- 2008-08-22 CA CA 2697262 patent/CA2697262A1/en not_active Abandoned
- 2008-08-22 JP JP2010521897A patent/JP2010536855A/ja active Pending
- 2008-08-22 MX MX2010002053A patent/MX2010002053A/es active IP Right Grant
-
2010
- 2010-02-23 IL IL204111A patent/IL204111A/en not_active IP Right Cessation
- 2010-02-26 ZA ZA2010/01427A patent/ZA201001427B/en unknown
-
2012
- 2012-07-02 IL IL220723A patent/IL220723A0/en unknown
-
2015
- 2015-08-07 JP JP2015157312A patent/JP2016040245A/ja active Pending
- 2015-09-03 US US14/844,642 patent/US20160115217A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ600171A (en) | 2014-01-31 |
| US20160115217A1 (en) | 2016-04-28 |
| RU2010110812A (ru) | 2011-09-27 |
| WO2009025867A3 (en) | 2009-12-30 |
| BRPI0815291A2 (pt) | 2015-02-03 |
| ZA201001427B (en) | 2011-05-25 |
| IL204111A (en) | 2015-08-31 |
| NZ618129A (en) | 2015-05-29 |
| JP2010536855A (ja) | 2010-12-02 |
| EP2193143A2 (en) | 2010-06-09 |
| KR20100076947A (ko) | 2010-07-06 |
| AU2008289462B2 (en) | 2014-01-23 |
| NZ583649A (en) | 2012-06-29 |
| AU2008289462A1 (en) | 2009-02-26 |
| EP2193143A4 (en) | 2012-01-25 |
| CN101883786A (zh) | 2010-11-10 |
| SG183763A1 (en) | 2012-09-27 |
| EP2193143B1 (en) | 2016-06-08 |
| RU2532830C2 (ru) | 2014-11-10 |
| JP2016040245A (ja) | 2016-03-24 |
| US20110008342A1 (en) | 2011-01-13 |
| IL220723A0 (en) | 2012-08-30 |
| WO2009025867A2 (en) | 2009-02-26 |
| MX2010002053A (es) | 2010-07-28 |
| US9127085B2 (en) | 2015-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9127085B2 (en) | Compositions of humanized notch fusion proteins and methods of treatment | |
| JP2010536855A5 (enExample) | ||
| US8993725B2 (en) | Notch-based fusion proteins and uses thereof | |
| US9475855B2 (en) | Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling | |
| He et al. | Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis | |
| AU2009200385A1 (en) | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs | |
| JP2009515520A (ja) | 肝細胞成長因子イントロン融合蛋白 | |
| EP2120996A2 (en) | Methods for using and identifying modulators of delta-like 4 | |
| RU2691104C2 (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| KR20010042364A (ko) | 성숙 ＦＬＩＮＴ(ｍＦＬＩＮＴ) 폴리펩타이드 또는 ＴＮＦ수용체인 ＯＰＧ3의 치료학적 용도 | |
| Tsai et al. | The novel VEGF121-VEGF165 fusion attenuates angiogenesis and drug resistance via targeting VEGFR2-HIF-1α-VEGF165/Lon signaling through PI3K-AKT-mTOR pathway | |
| JP2004506595A (ja) | 血管形成及び心臓血管新生の促進又は阻害 | |
| HK1151983B (en) | Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling | |
| CA3123167A1 (en) | Chimeric antigen receptors (cars) and their use in medicine | |
| NZ525221A (en) | Vectors encoding LAP (transcriptor activator) and LIP activity expressed from the C/EBP beta gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130815 |
|
| FZDE | Discontinued |
Effective date: 20180108 |